Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia

Peter C. Trask, David Cella, Nadine Besson, Virginia Kelly, T. Masszi, Dong Wook Kim

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96. weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.

Original languageEnglish
Pages (from-to)438-442
Number of pages5
JournalLeukemia Research
Volume36
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Leukemia, Myeloid, Chronic Phase
Quality of Life
Leukemia
Therapeutics
Protein-Tyrosine Kinases
Imatinib Mesylate
bosutinib
Neoplasms
Survival

Keywords

  • Bosutinib
  • Chronic myeloid leukemia
  • Chronic phase
  • FACT-Leu
  • Health-related quality of life

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. / Trask, Peter C.; Cella, David; Besson, Nadine; Kelly, Virginia; Masszi, T.; Kim, Dong Wook.

In: Leukemia Research, Vol. 36, No. 4, 04.2012, p. 438-442.

Research output: Contribution to journalArticle

Trask, Peter C. ; Cella, David ; Besson, Nadine ; Kelly, Virginia ; Masszi, T. ; Kim, Dong Wook. / Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. In: Leukemia Research. 2012 ; Vol. 36, No. 4. pp. 438-442.
@article{52d7943761de4b64b8ccc8252fee87fd,
title = "Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia",
abstract = "Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96. weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.",
keywords = "Bosutinib, Chronic myeloid leukemia, Chronic phase, FACT-Leu, Health-related quality of life",
author = "Trask, {Peter C.} and David Cella and Nadine Besson and Virginia Kelly and T. Masszi and Kim, {Dong Wook}",
year = "2012",
month = "4",
doi = "10.1016/j.leukres.2011.10.011",
language = "English",
volume = "36",
pages = "438--442",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia

AU - Trask, Peter C.

AU - Cella, David

AU - Besson, Nadine

AU - Kelly, Virginia

AU - Masszi, T.

AU - Kim, Dong Wook

PY - 2012/4

Y1 - 2012/4

N2 - Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96. weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.

AB - Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96. weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.

KW - Bosutinib

KW - Chronic myeloid leukemia

KW - Chronic phase

KW - FACT-Leu

KW - Health-related quality of life

UR - http://www.scopus.com/inward/record.url?scp=84857234074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857234074&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.10.011

DO - 10.1016/j.leukres.2011.10.011

M3 - Article

VL - 36

SP - 438

EP - 442

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 4

ER -